血管化复合同种异体移植的干细胞治疗进展

Stem cell therapy on vascular composite allotransplantation

血管化复合同种异体移植是指来自不同胚层的多种组织构成的复合移植,可显著提高患者术后外形、功能和生活质量。皮肤排斥是血管化复合同种异体移植免疫不耐受的关键,术后需长期使用免疫抑制剂,因此导致多种急性和慢性并发症,是目前血管化复合同种异体移植广泛应用的主要障碍。干细胞的营养和旁分泌作用,抑制炎症反应和免疫抑制调节特性,在血管化复合同种异体移植免疫耐受的相关研究中得到了广泛关注。该文对当前血管化复合同种异体移植的干细胞治疗的研究进展进行综述,为开展相关研究提供参考。

Vascular composite allotransplantation(VCA)is a composite transplantation composed of various tissues from different germ layers,which can significantly improve the living condition of patients.Skin repulsion plays a crucial role in VCA immune intolerance.Long-term use of immunosuppressive agents post-operatively leads to a variety of acute and chronic complication,which currently is the main obstacle to the widespread use of VCA.The function of secretion,inhibition of inflammatory response and immunosuppressive regulation properties of stem cells has received significant attention in VCA immune intolerance studies.This article reviewed the current research progress of stem cell therapy for VCA,providing a reference for relevant research.